Dr. Resnick's research focuses on the cell signaling mechanisms of oncogenesis and tumor progression in brain tumors. He studies signaling cascades and alterations to elucidate the molecular and genetic underpinnings in order to develop targeted therapies. As co-director of the Center of Data-Driven Discovery in Biomedicine, he leads a multidisciplinary team building and supporting a scalable, patient-focused healthcare and educational discovery ecosystem.
Dr. Balis's research focuses on the clinical pharmacology of anticancer drugs, new drug development, and clinical trial design and endpoints. He studies the pharmacokinetics and pharmacodynamics of anticancer drugs and has applied pharmacological principles to clinical trial design and clinical drug development. He is developing new biomarkers to serve as surrogate endpoints of drug toxicity or efficacy in clinical trials.
Dr. MacFarland's research focuses on syndromes that predispose to cancer development in children and adolescents. She has initiated several individual and collaborative research projects, working in pediatric polyposis syndromes and Li-Fraumeni syndrome. She is uncovering novel genomic drivers of disease and identifying biomarkers of cancer onset and progression.
Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells.